This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
NewLink Genetics Corporation
Drug Names(s): algenpantucel-L, HyperAcute-Pancreatic Cancer Vaccine
Description: HyperAcute cancer immunotherapies are off-the-shelf products composed of a mixture of irradiated, allogeneic, whole cancer cells that have been genetically modified to add a(1,3)-Galactosyl (aGal) residues to cell-surface lipids and proteins. The aGal epitopes function as a molecular adjuvant, effectively harnessing the mechanism responsible for hyperacute rejection of xenotransplants.
NewLink's HyperAcute technology yields a unique combination of advantages, including:
- Rapid and strong onset of immune response triggered by pre-existing, naturally occurring, high-titer antibodies to aGal;
- Complement-mediated cell lysis generating immune system danger signals that elicit activation and recruitment of antigen presenting cells (APCs);
- Anti-aGal-dependent generation of multiple immune responses engaging dendritic cells, macrophages, eosinophils, and NK cells; and
- FcvR-mediated phagocytosis and tumor-associated antigen (TAA) uptake by APCs resulting in activation of both cytotoxic CD8+ T-cells and CD4+ helper T-cells, as well as activation and differentiation of tumor antigen-specific B-cells.
HyperAcute Pancreas News
Pink Sheet Pancreatic Cancer Drugs In Development
Additional information available to subscribers only: